Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease

被引:43
作者
Church, H.
Tylee, K.
Cooper, A.
Thornley, M.
Mercer, J.
Wraith, E.
Carr, T.
O'Meara, A.
Wynn, R. F. [1 ]
机构
[1] Royal Manchester Childrens Hosp, Dept Haematol BMT, Manchester M27 4HA, Lancs, England
[2] Royal Manchester Childrens Hosp, Willink Unit Biochem Genet, Dept Paediat, Manchester M27 1HA, Lancs, England
[3] Our Ladys Hosp Sick Children, Dept Paediat Oncol BMT, Dublin 12, Ireland
关键词
Hurler; chimerism; GAG; BONE-MARROW-TRANSPLANTATION; CHILDREN;
D O I
10.1038/sj.bmt.1705569
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Hurler Syndrome is corrected by allogeneic BMT by the action of donor enzyme on recipient tissue. In this paper, we describe monitoring of 39 patients transplanted in two centres to determine donor chimerism, enzyme level and residual substrate - expressed as dermatan sulphate to chondroitin sulphate ratio. We show that in fully engrafted recipients, the enzyme level, expressed as mu mol/g total protein/h, post-transplant is 24.2 from an unrelated donor and 10.2 from a heterozygote family donor (P < 0.0001). There is a tight relationship between mean post-transplant enzyme level and residual substrate Spearman's rank correlation coefficient (Rho) was -0.76 and -0.80 at 12 and 24 months, respectively (P < 0.0001). We propose that these differences affect patient outcome. As unrelated donor transplant outcomes improve and especially given the higher levels of donor cell engraftment following cord transplants, our data might influence donor selection where only heterozygote-matched family members are available.
引用
收藏
页码:207 / 210
页数:4
相关论文
共 13 条
[11]   Bone marrow transplantation for mucopolysaccharidosis type I: Experience of two British centres [J].
Vellodi, A ;
Young, EP ;
Cooper, A ;
Wraith, JE ;
Winchester, B ;
Meaney, C ;
Ramaswami, U ;
Will, A .
ARCHIVES OF DISEASE IN CHILDHOOD, 1997, 76 (02) :92-99
[12]  
WHITEMAN P, 1973, LANCET, V1, P1249
[13]   Enzyme replacement therapy for mucopolysaccharidosis I:: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (Laronidase) [J].
Wraith, JE ;
Clarke, LA ;
Beck, M ;
Kolodny, EH ;
Pastores, GM ;
Muenzer, J ;
Rapoport, DM ;
Berger, KI ;
Swiedler, SJ ;
Kakkis, ED ;
Braakman, T ;
Chadbourne, E ;
Walton-Bowen, K ;
Cox, GF .
JOURNAL OF PEDIATRICS, 2004, 144 (05) :581-588